TITLE

Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial

AUTHOR(S)
Poland, Gregory A.; Jacobson, Robert M.; Koutsky, Laura A.; Tamms, Gretchen M.; Railkar, Radha; Smith, Judith F.; Bryan, Janine T.; Cavanaugh, Paul F.; Jansen, Kathrin U.; Barr, Eliav
PUB. DATE
May 2005
SOURCE
Mayo Clinic Proceedings;May2005, Vol. 80 Issue 5, p601
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To evaluate the immunogenicity, reactogenicity, and tolerability of a prototype human papillomavirus (HPV) 16 virusilke particle (VLP) vaccine directed against the L1 capsid protein. SUBJECTS AND METHODS: We enrolled healthy nonpregnant women aged 18 to 26 years into a 2-year, double-blind, dose-ranging multicenter trial (October 12, 1998, to September 30, 2001). Subjects were assigned to study groups to receive a 3-dose regimen (day 0, month 2, and month 6) of 1 of 4 vaccine doses: 10 μg, 20 μg, 40 μg, or 80 μg or placebo. Serum anti-HPV 16 L1 antibody (sL1Ab) geometric mean titers (GMTs) were measured at day 0, at month 3, at month 7, and every 6 months for a total of 2 yeas using a radioimmunoassay. The primary immunogenicity analyses evaluated GMTs at month 7 in L1Ab-seronegative subjects at baseline. Vaccine tolerability was also assessed. RESULTS: A total of 480 subjects were randomized to receive placebo (n=52) or 10 μg (n=112), 20 μg (n=103), 40 μg (n=104), or 80 μg (n=107) of HPV 16 L1 VLP vaccine. At baseline, 75% of subjects were L1Ab seronegative. All vaccine doses produced a statistically significant sL1Ab response vs placebo (P<.001). At the completion of the vaccination regimen, sL1Ab GMTs in baseline-seronegative subjects were 36- to 78-told higher than the sL1Ab GMT at day 0 observed in subjects who had mounted an immune response to HPV 16 infection before enrollment. Serum L1Ab GMTs remained high throughout the 1.5-year postvaccinadon period. Poetvaccination sL1Ab GMTs were 1.1- to 2.4-fold higher in women who had detectable sL1Ab levels at enrollment compared with those in baseline-seronegative subjects, particularty in the persistence phase. The vaccine was generally well tolerated with no statistically significant differences in injection site or systemic adverse experiences among treatment groups. CONCLUSION: Immunization with this novel HPV 16 L1 VLP vaccine was well tolerated and produced an immunogenic response that persisted for at least 1.5 years after the final dose.
ACCESSION #
17019223

 

Related Articles

  • Reducing the Dose of Smallpox Vaccine Reduces Vaccine-Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses. Couch, Robert B.; Winokur, Patricia; Edwards, Kathryn M.; Black, Steven; Atmar, Robert L.; Stapleton, Jack T.; Kissner, Jennifer M.; Shinefield, Henry; Denny, Thomas N.; Bybel, Michael J.; Newman, Frances K.; Lihan Yan // Journal of Infectious Diseases;3/15/2007, Vol. 195 Issue 6, p826 

    Background. When the decision was made to prepare for a deliberate release of smallpox, the United States had ~15 million doses of Wyeth Dryvax vaccine, which was known to induce significant morbidity when used undiluted; Sanofi Pasteur, Inc., later identified ~85 million additional doses in...

  • Serum-Induced Iron-Acquisition Systems and TonB Contribute to Virulence in Klebsiella pneumoniae Causing Primary Pyogenic Liver Abscess. Pei-Fang Hsieh; Tzu-Lung Lin; Cha-Ze Lee; Shih-Feng Tsai; Jin-Town Wang // Journal of Infectious Diseases;6/15/2008, Vol. 197 Issue 12, p1717 

    Background. Klebsiella pneumoniae has become the predominant pathogen causing primary pyogenic liver abscess (PLA). Methods. K. pneumoniae was stimulated by human serum, and gene expression was analyzed by microarray. Results. Three putative iron acquisition systems, Yersinia high-pathogenicity...

  • Reply to Harper. LaMontagne, D. Scott // Journal of Infectious Diseases;Jul2014, Vol. 210 Issue 2, p331 

    A reply from the authors of the article "Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29â€"32 months after third dose" in a 2013 issue is presented.

  • Nasal Spray Halts Alzheimer's in Mice. Netting, Jessa Forte // Discover;Jan2006, Vol. 27 Issue 1, p48 

    The article reports that a drug combination that stirs up an immune response in the brain might provide a treatment for Alzheimer's disease. A team of neurologists at Brigham and Women's Hospital in Boston, Massachusetts reported that a nasal spray containing the drugs cleared more than 80...

  • Immune response studies with Wuchereria bancrofti vespid allergen homologue (WbVAH) in human lymphatic filariasis. Setty Anand; Munirathinam Gnanasekar; Mani Thangadurai; Prince Prabhu; Perumal Kaliraj; Kalyanasundaram Ramaswamy // Parasitology Research;Sep2007, Vol. 101 Issue 4, p981 

    Abstract  A homologue of Brugia malayi venom allergen (BmVAH) was cloned from the infective stages (L3) of Wuchereria bancrofti. Sequence analysis showed 90% sequence identity between WbVAH and BmVAH. Recombinant WbVAH was then expressed and purified. VAH from other nematode...

  • Local and Systemic Up-regulation of TNFα, IL-1β and IL-6 in Mice Intratracheally Inoculated with Porphyromonas gingivalis. Pavlica, Z.; Nemec, A.; Nemec-Svete, A.; Eržen, D.; Crossley, D. A.; Petelin, M. // Acta Veterinaria Brno;Sep2008, Vol. 77 Issue 3, p377 

    The objective of the study was to find whether a single intratracheal inoculation with live Porphyromonas gingivalis ATCC 33277 influences local and systemic inflammatory and immune responses in mice. Twelve-week-old BALB/c mice were intratracheally inoculated with 2.9 × 109 CFU P....

  • seroconversion.  // Taber's Cyclopedic Medical Dictionary;2005, p1977 

    A definition of the term "seroconversion" is presented. It refers to the development of an antibody response caused by an infection or vaccine, that can be measured in the serum.

  • Immune Responses and Protective Efficacy of the Gene Vaccine Expressing Ag85B and ESAT6 Fusion Protein from Mycobacterium tuberculosis. Shi Chang-hong; Wang Xiao-wu; Zhang Hai; Zhang Ting-fen; Wang Li-mei; Xu Zhi-kai // DNA & Cell Biology;Apr2008, Vol. 27 Issue 4, p199 

    Genetic immunity is a new promising approach for the development of novel tuberculosis vaccines. In this study, it is shown that DNA vaccines expressing the fusion protein of antigen 85B (Ag85B) and early secreted antigenic target 6-kDa antigen (ESAT6) can induce high levels of specific IgG2a...

  • Vaccines in the public eye. Ritvo, Paul; Wilson, Kumanan; Willms, Dennis; Upshur, Ross; Goldman, Adam; Kelvin, David; Rosenthal, Kenneth L.; Rinfret, Aline; Kaul, Rupert; Krahn, Murray // Nature Medicine;Apr2005 Supplement, Vol. 11, p20 

    Preventive vaccines are widely acknowledged as the best hope for protection against infectious pathogens such as avian flu, HIV and SARS. As a result, they have received much recent attention in the media that has exposed some of the challenges involved in optimally using vaccine technology.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics